Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing

作者：Stéphanie Barrère‐Lemaire, Anne Vincent, Christian Jørgensen, Christophe Piot, Joël Nargeot, Farida Djouad · 发表于：Physiological Reviews · 年份：2023 · DOI：10.1152/physrev.00009.2023 · 被引用次数：81 · 研究领域：Mesenchymal stem cell research、Cardiac Ischemia and Reperfusion、Cardiovascular Function and Risk Factors

Acute myocardial infarction (AMI) is the leading cause of cardiovascular death and remains the most common cause of heart failure. Reopening of the occluded artery, i.e., reperfusion, is the only way to save the myocardium. However, the expected benefits of reducing infarct size are disappointing due to the reperfusion paradox, which also induces specific cell death. These ischemia-reperfusion (I/R) lesions can account for up to 50% of final infarct size, a major determinant for both mortality and the risk of heart failure (morbidity). In this review, we provide a detailed description of the cell death and inflammation mechanisms as features of I/R injury and cardioprotective strategies such as ischemic postconditioning as well as their underlying mechanisms. Due to their biological properties, the use of mesenchymal stromal/stem cells (MSCs) has been considered a potential therapeutic approach in AMI. Despite promising results and evidence of safety in preclinical studies using MSCs, the effects reported in clinical trials are not conclusive and even inconsistent. These discrepancies were attributed to many parameters such as donor age, in vitro culture, and storage time as well as injection time window after AMI, which alter MSC therapeutic properties. In the context of AMI, future directions will be to generate MSCs with enhanced properties to limit cell death in myocardial tissue and thereby reduce infarct size and improve the healing phase to increase postinfarct myocard...